Update on drugs for hyperactivity in childhood.
In 2001, we concluded that methylphenidate or dexamfetamine can be useful adjunctive therapy for children with severe hyperactivity in whom non-drug approaches alone have been inadequate. Since then, atomoxetine (pronounced a-toe-moks-e-teen; Strattera - Lilly) and three modified-release formulations of methylphenidate have been launched for attention deficit hyperactivity disorder (ADHD). Here we reconsider drugs for ADHD in childhood, focusing on the newer products.
D018759:Adrenergic Uptake Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000191:economics; D000697:Central Nervous System Stimulants / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003692:Delayed-Action Preparations; D003913:Dextroamphetamine / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D006801:Humans; D008774:Methylphenidate / Q000191:economics / Q000627:therapeutic use; D011437:Propylamines / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride; D003913:Dextroamphetamine